# Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

> **NCT00543972** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 12 (actual)

## Conditions studied

- Myeloid Leukemia

## Interventions

- **DRUG:** AVE9633

## Key facts

- **NCT ID:** NCT00543972
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** due to absence of evidence of clinical activity up to toxic doses
- **Last updated:** 2009-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543972, "Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00543972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*